Bell Investment Advisors’s Immunic IMUX Stock Holding History

Bell Investment Advisors’s Portfolio IMUX Stock Details IMUX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-65	Closed	-$573	–	1864
2025 Q3	$573	Buy	+65	New	+$573	﹤0.01%	1726

Other funds holding IMUX

Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Focus Partners Wealth Boston, Massachusetts $89.9B AUM 20.5% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Bell Investment Advisors's IMUX Position: Q4 2025 in Review

Bell Investment Advisors sold out of Immunic (IMUX) in Q4 2025, closing a stake of 65 shares — an estimated $573 sold.

Bell Investment Advisors first reported a position in IMUX in Q3 2025 and held it in 1 quarter. The position peaked at $573 in Q3 2025. 58 funds tracked by Wall St. Rank hold IMUX as of Q4 2025.

Bell Investment Advisors reported no remaining Immunic position as of Q4 2025 after selling out during the quarter.
Bell Investment Advisors sold 65 Immunic shares in Q4 2025, an estimated $573.
Bell Investment Advisors first reported a position in Immunic in Q3 2025 and held it in 1 quarter.
Bell Investment Advisors's Immunic position peaked at $573 in Q3 2025.
58 funds tracked by Wall St. Rank held Immunic as of Q4 2025.

Based on Bell Investment Advisors's 13F filing for Q4 2025, filed 24 Feb 2026.